Rebiotix completes Phase 3 trial enrollment

Investigators have completed enrollment in a phase 3 trial set to investigate RBX2660 from Rebiotix, a therapy that uses the gut microbiota to treat Clostridioides difficile infection.

“Microbiota-based therapies have shown tremendous potential as an innovative, non-antibiotic therapy, starting with C. diff,” said Rebiotix founder and CEO Lee Jones. more